Search

Your search keyword '"Jetske Meerum Terwogt"' showing total 3 results
Start Over Author "Jetske Meerum Terwogt"
3 results on '"Jetske Meerum Terwogt"'

1. Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial

Author

Mark Opdam, Annelot G.J. van Rossum, Marlous Hoogstraat, Gergana Bounova, Hugo M. Horlings, Erik van Werkhoven, Ingrid A.M. Mandjes, A. Elise van Leeuwen – Stok, Sander Canisius, Harm van Tinteren, Alex L.T. Imholz, Johanneke E.A. Portielje, Monique E.M.M. Bos, Sandra Bakker, Jelle Wesseling, Lennart Kester, Jacco van Rheenen, Emiel J. Rutgers, Renee X. de Menezes, Lodewyk F.A. Wessels, Marleen Kok, Hendrika M. Oosterkamp, Sabine C. Linn, Marcel Soesan, Rianne M. Oosterkamp, Frank Jeurissen, Nir Weijl, Karin J. Beelen, Aart van Bochove, Gerty de Klerk, Suzan Vrijaldenhoven, Annette van der Velden, Hiltje de Graaf, Marielle Smeets, Jetske Meerum Terwogt, Jolanda Schrama, Philomeen Kuijer, Hanneke Wilmink, Ronald Hoekstra, Judith Kroep, Hans F.M. Pruijt, Leander van Gerven, Allert H. Vos, Frans Erdkamp, Willemien G. van Leeuwen-Breuk, and Alexander de Graeff

Subjects
Cancer, Clinical genetics, Oncology, Science
Abstract

Summary: The primary objective of the prospective, randomized, multicenter, phase 3 biomarker Microarray Analysis in breast cancer to Taylor Adjuvant Drugs Or Regimens trial (MATADOR: ISRCTN61893718) is to generate a gene expression profile that can predict benefit from either docetaxel, doxorubicin, and cyclophosphamide (TAC) or dose-dense scheduled doxorubicin and cyclophosphamide (ddAC). Patients with a pT1-3, pN0-3 tumor were randomized 1:1 between ddAC and TAC. The primary endpoint was a gene profile-treatment interaction for recurrence-free survival (RFS). We observed 117 RFS events in 664 patients with a median follow-up of 7 years. Hallmark gene set analyses showed significant association between enrichment in immune-related gene expression and favorable outcome after TAC in hormone receptor-negative, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC) (triple-negative breast cancer [TNBC]). We validated this association in TNBC patients treated with TAC on H&E slides; stromal tumor-infiltrating lymphocytes (sTILs) ≥20% was associated with longer RFS (hazard ratio 0.18, p = 0.01), while in patients treated with ddAC no difference in RFS was seen (hazard ratio 0.92, p = 0.86, pinteraction = 0.02).

Published
2024
Full Text
View/download PDF

2. The prognostic value of the 12‐, 6‐, 3‐ and 1‐month ‘Surprise Question’ in cancer patients: A prospective cohort study in three hospitals

Author

Arianne Stoppelenburg, Müzeyyen Arslan, Catherine Owusuaa, Nicolette Gunnink, Yvette M. van der Linden, Saskia A. C. Luelmo, Jetske Meerum‐Terwogt, Annemieke van der Padt‐Pruijsten, Daan Nieboer, Agnes van der Heide, Public Health, and Medical Oncology

Subjects
SDG 3 - Good Health and Well-being, Oncology, Surprise Question, Neoplasms, Palliative Care, cancer, Humans, observational study, Prospective Studies, hospital, Prognosis, Hospitals
Abstract

Objective: This prospective study aimed to evaluate the performance of the ‘Surprise Question’ (SQ) ‘Would I be surprised if this patient died in the next 12 months?’ in predicting survival of 12, 6, 3 and 1 month(s), respectively, in hospitalised patients with cancer. Methods: In three hospitals, physicians were asked to answer SQs for 12/6/3/1 month(s) for inpatients with cancer. Sensitivity, specificity, positive and negative predictive values were calculated. Results: A total of 783 patients were included, of whom 51% died in the 12-month period after inclusion. Sensitivity of the SQ predicting death within 12 months was 0.79, specificity was 0.66, the positive predictive value was 0.71 and the negative predictive value was 0.75. When the SQ concerned a shorter survival period, sensitivities and positive predictive values decreased, whereas specificities and negative predictive values increased. In multivariable logistic regression analysis, the SQ was significantly associated with mortality (OR 3.93, 95% CI 2.70–5.71, p < 0.01). Conclusions: The 12-month SQ predicts death in patients with cancer admitted to the hospital reasonably well. Shortening the timeframe decreases sensitivities and increases specificities. The four surprise questions may help to identify patients for whom palliative care is indicated.

Published
2022

3. The COMPASS study: A descriptive study on the characteristics of palliative care team consultation for cancer patients in hospitals

Author

Lia van Zuylen, Jetske Meerum-Terwogt, Ellen J M de Nijs, Annemiek van der Padt-Pruijsten, Agnes van der Heide, Hester F. Lingsma, Suzanne Polinder, Liesbeth A Peters, Maurice J. D. L. van der Vorst, Arianne Brinkman-Stoppelenburg, Public Health, Medical Oncology, CCA - Cancer Treatment and quality of life, and Medical oncology

Subjects
Male, medicine.medical_specialty, Palliative care, Nurses, 03 medical and health sciences, 0302 clinical medicine, Life Expectancy, SDG 3 - Good Health and Well-being, General Practitioners, Neoplasms, Adaptation, Psychological, Medicine, Humans, Pain Management, Nurse Practitioners, Referral and Consultation, Fatigue, Aged, Netherlands, Oncologists, Patient Care Team, business.industry, Palliative Care, Cancer, Cancer Pain, Middle Aged, medicine.disease, Hospitals, Anesthesiologists, Hospitalization, Dyspnea, Oncology, Palliative care.team, Withholding Treatment, 030220 oncology & carcinogenesis, Family medicine, Life expectancy, Female, Patient Care, Descriptive research, business
Abstract

Objective: To describe the characteristics of palliative care team (PCT) consultation for patients with cancer who are admitted in hospital and to investigate when and why PCTs are consulted. Methods: In this descriptive study in ten Dutch hospitals, the COMPASS study, we compared characteristics of patients with cancer for whom a PCT was or was not consulted (substudy 1). We also collected information about the process of PCT con‐ sultations and the disciplines involved (substudy 2). Results: In substudy 1, we included 476 patients. A life expectancy

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results